LabGenius & Sanofi partnership yields positive results from AI antibody discovery platform

Today, LabGenius, a pioneer in the use of AI and machine learning for antibody discovery, releases new data from its antibody discovery platform following a multi-year collaboration with Sanofi.

The results confirm that LabGenius’ antibody discovery technology is able to co-optimize the pre-determined properties of a monovalent NANOBODY® protein whilst maintaining favorable production characteristics.

More generally, the partnership demonstrates that Big Pharma are committing to their pledge to put AI at the centre of their drug discovery efforts.

  • About the partnership: In 2021, LabGenius and Sanofi initiated a multi-year collaboration in the area of inflammation that combined LabGenius’ capabilities in machine learning (ML), robotic automation, and synthetic biology with Sanofi’s expertise in the therapeutic development of NANOBODY® heavy chain variable domains.
  • The results: LabGenius confirmed that the 10 most improved NANOBODY® variants demonstrated up to a 7-fold improvement in the desired property of interest, whilst maintaining the potency of the starting molecule.
  • What it means: The results represent a significant milestone for LabGenius, demonstrating the ability of its antibody discovery platform to accelerate the development of molecules with unique and important properties.

LabGenius presented the data in a poster at the Single-Domain Antibodies 2023 Meeting in Paris. You can find the poster here.

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    LabGenius. (2023, September 19). LabGenius & Sanofi partnership yields positive results from AI antibody discovery platform. News-Medical. Retrieved on June 20, 2024 from https://www.news-medical.net/news/20230919/LabGenius-Sanofi-partnership-yields-positive-results-from-AI-antibody-discovery-platform.aspx.

  • MLA

    LabGenius. "LabGenius & Sanofi partnership yields positive results from AI antibody discovery platform". News-Medical. 20 June 2024. <https://www.news-medical.net/news/20230919/LabGenius-Sanofi-partnership-yields-positive-results-from-AI-antibody-discovery-platform.aspx>.

  • Chicago

    LabGenius. "LabGenius & Sanofi partnership yields positive results from AI antibody discovery platform". News-Medical. https://www.news-medical.net/news/20230919/LabGenius-Sanofi-partnership-yields-positive-results-from-AI-antibody-discovery-platform.aspx. (accessed June 20, 2024).

  • Harvard

    LabGenius. 2023. LabGenius & Sanofi partnership yields positive results from AI antibody discovery platform. News-Medical, viewed 20 June 2024, https://www.news-medical.net/news/20230919/LabGenius-Sanofi-partnership-yields-positive-results-from-AI-antibody-discovery-platform.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.